Breaking News, Financial News

Financial Report: Roche

Nutley closure impacts earnings

Roche
 
1H Revenues: $25.5 billion (+4%)

1H Earnings: $4.6 billion (-14%)

Comments: Pharmaceutical sales were $18.2 billion (+4%). Growth in the half was driven by cancer medicines, hepatitis drug Pegasys, rheumatoid arthritis treatment Actemra/RoActemra and the clinical lab business. Earnings decline was mainly due to costs related to closure of Nutley, NJ operations and productivity measures in Applied Science and Diabetes Care.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters